Vericel Corp

Stage 2 advance remains intact with accelerating uptrend (Parabola) but price is extremely overbought and extended above rising EMAs. Medium-term bias stays bullish, but execution should wait for pullbacks into the rising EMA support zones given exhaustion risk.

• ↑Q1 total revenue $68.4M (+30% YoY); Macy segment $56.4M (+22%)
• ↑Burn Care revenue $12M (+90% YoY), underscoring Nexabrid's traction
• ↓Negative earnings yield and subpar profitability metrics raise margin concerns